Mesut Cetin

Mesut Cetin

Auto-generated profile, based on publicly available information

Mesut Cetin

Psychiatry &Clinical Psychopharmacology and Psychiatry and Behavioral Sciences, Istanbul, Turkey

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2008 in Psychiatry and Clinical Neurosciences
Verified
Journal Article
Closed access
PDF file
USUmit B. Semiz
Umit B. Semiz
CBCengiz Basoglu
Cengiz Basoglu
SEServet Ebrinc
Servet Ebrinc
MCMesut Cetin
Mesut Cetin

1 September 2003 in Comprehensive Psychiatry
Verified
Journal Article
Closed access
ÖUÖzcan Uzun
Özcan Uzun
CBCengiz Başoğlu
Cengiz Başoğlu
AAAhmet Akar
Ahmet Akar
ACAdnan Cansever
Adnan Cansever
AÖAytekin Özşahin
Aytekin Özşahin
SEServet Ebrinç
Servet Ebrinç

26 October 2005 in Journal of Traumatic Stress
Verified
Journal Article
Closed access
PDF file
MCMesut Cetin
Mesut Cetin
Samet KoseSamet Kose
Samet Kose
SEServet Ebrinc
Servet Ebrinc
SYSuat Yigit
Suat Yigit
JEJon D. Elhai
Jon D. Elhai
CBCengiz Basoglu
Cengiz Basoglu

1 January 2008 in Australian & New Zealand Journal of Psychiatry
Verified
Journal Article
Closed access
USUmit B. Semiz
Umit B. Semiz
CBCengiz Basoglu
Cengiz Basoglu
OOOzgur Oner
Ozgur Oner
KMKerim M Munir
Kerim M Munir
AAAlpay Ates
Alpay Ates
MCMesut Cetin
Mesut Cetin
Objective: Although children with attention deficit hyperactivity disorder (ADHD) are at increased risk for later onset of antisocial personality disorder (APD) as adults, the utility of ADHD as either a comorbid diagnosis (ADHD c ) or dimensional symptoms (ADHD d ) in predicting behaviour and substance use problems in APD subjects has not been examined. Method: A total of 105 adult male offenders with Structured Clinical Interview for Axis II Disorders (SCID-II)-based DSM-III-R APD were studied in terms of: (i) psychopathy scores on the Hare Psychopathy Checklist–Revised (PCL-R); (ii) ADHD c diagnostic comorbidity on clinically administered DSM-IV questionnaire; and (iii) ADHD d dimensional symptoms by means of Wender Utah Rating Scale (WURS) and Conners Adult ADHD Rating Scale (CAARS) during a 12 month study period (May 2005–May 2006). Results: Sixty five per cent of APD subjects met criteria for ADHD c diagnostic comorbidity with significantly increased rates of childhood neglect, parental divorce and suicide attempt, but not of psychopathy. APD subjects with ADHD d symptoms were noted to have earlier onset and increased rate of self-injurious behaviour (SIB), suicide attempt, and psychopathy. The psychopathy scores, in turn, were predictive of earlier onset of SIB and behavioural problems. Conclusion: Both ADHD c diagnostic comorbidity and ADHD d symptoms need to be assessed in APD subjects and the dimensional measures may be better in detecting earlier onset SIB, suicide attempt and other behavioural problems.

1 May 2010 in International Clinical Psychopharmacology
Verified
Journal Article
Closed access
CBCengiz Basoglu
Cengiz Basoglu
OOOzgur Oner
Ozgur Oner
CGCengiz Gunes
Cengiz Gunes
USUmit B. Semiz
Umit B. Semiz
AAAlpay M. Ates
Alpay M. Ates
OIOsman Ipcioglu
Osman Ipcioglu
The objective of the study was to investigate the change of body mass index (BMI), waist circumference, lipid profile, leptin, ghrelin, orexin, visfatin, agouti-related protein, and cholecystokinin levels during 6 weeks of olanzapine treatment in newly diagnosed first-episode drug naive, young adult, nonobese male patients with psychosis. Twenty male participants who were all first-episode drug naive psychotic patients without prominent affective signs and symptoms and 22 healthy male controls of similar age were included. BMI, waist circumference, fasting glucose, and lipid profiles were measured, and Positive and Negative Syndrome Scale and Brief Psychiatric Rating Scale scores were obtained at baseline, during the second and sixth week of treatment, and the aforementioned neuropeptide levels were measured at baseline and during the sixth week of treatment. Treatment was associated with significant increases in BMI, waist circumference, serum triglyceride, and low-density lipoprotein levels. BMI levels increased more than 7% in over 75% of the patients. Leptin increased, and ghrelin and orexin decreased significantly with olanzapine treatment, whereas cholecystokinin, visfatin, and agouti-related protein levels did not change significantly. In conclusion, consistent with previous studies, we found increased BMI, leptin and lipids during olanzapine treatment. Association of neuropeptide level changes with symptom improvement might be mediated by the dopaminergic and serotonergic systems.

12 June 2007 in Progress in Neuro-Psychopharmacology and Biological Psychiatry
Verified
Journal Article
Closed access
USUmit B. Semiz
Umit B. Semiz
MCMesut Cetin
Mesut Cetin
CBCengiz Basoglu
Cengiz Basoglu
SEServet Ebrinc
Servet Ebrinc
OUOzcan Uzun
Ozcan Uzun
AAAlpay Ates
Alpay Ates